Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what progress NHS England has made on integrating Wegovy to existing weight management structures within primary care settings.

The National Institute for Health and Care Excellence’s guidance on semaglutide, the active ingredient in wegovy, for managing overweight and obesity was published in March 2023, and updated in September 2023. It recommends semaglutide as a treatment option for patients that meet specified eligibility criteria, and recommends that the treatment is provided within specialist weight management services. These services are typically provided in secondary rather than primary care settings. The Government is committed to the safe introduction of new weight loss drugs into the National Health Service, and is exploring ways to increase access to more people, who meet the relevant eligibility criteria.